SCHEMBL871636

SCHEMBL871636

CS(=O)(=NC(=O)c1cncc(-c2ccccc2)c1)C1C=CC=CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 2/20 0.40
MKNK1 Q9BUB5 3/20 0.36
MKNK2 Q9HBH9 3/20 0.36
XDH P47989 2/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
CTSA P10619 2/20 0.34
KDR P35968 3/20 0.33
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PI4KA P42356 1/20 0.32
PIK3CG P48736 1/20 0.32
PIK3C3 Q8NEB9 1/20 0.32
PI4KB Q9UBF8 1/20 0.32
SCN2A Q99250 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
PDGFRB P09619 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11985203 1.00 KAT6A (0.40) KAT6AMKNK1MKNK2XDHBRD4
SCHEMBL10182185 0.92 KMO (0.41) KAT6AMKNK1MKNK2XDH
SCHEMBL870934 0.92 XDH (0.45) KAT6AMKNK1MKNK2XDH
SCHEMBL11985268 0.91 MKNK1 (0.34) KAT6AMKNK1MKNK2XDHSCN10A
SCHEMBL11985204 0.90 SCN10A (0.40) MKNK1MKNK2XDHBRD4KDR
SCHEMBL871880 0.90 SCN10A (0.40) MKNK1MKNK2XDHBRD4KDR
SCHEMBL872183 0.87 CTSA (0.38) KAT6ACTSAKDRCYP11B1CYP11B2
SCHEMBL11985143 0.87 CTSA (0.38) KAT6ACTSAKDRCYP11B1CYP11B2
SCHEMBL871769 0.86 PIP4K2A (0.49) KDRCYP11B2PDGFRBPIP4K2APIP4K2B
SCHEMBL869367 0.85 XDH (0.49) MKNK1MKNK2XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383825-B2 Kinase inhibitors ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-8143410-B2 Kinase inhibitors ALLERGAN, INC. (US) 2012-03-27 US disclosed
US-20110263611-A1 Kinase Inhibitors ALLERGAN, INC. 2011-10-27 US disclosed
US-20090196906-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263611-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 KAT6A 1107/4885MKNK1 40/4885MKNK2 49/4885
US-20090196906-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 KAT6A 1107/4885MKNK1 40/4885MKNK2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.